BioSpace News Archive

We have completed the manufacturing of GP2, released 3 clinical lots, and started the stability testing program for these lots.

Centogene N.V., the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, as part of a consortium of organizations in genetics, announced the release of updated recommendations for Whole Genome Sequencing in the rare disease diagnostic setting.

ImmunoGen, Inc. announced that the US Food and Drug Administration has accepted and filed the Biologics License Application for mirvetuximab soravtansine monotherapy in patients with folate receptor alpha -high platinum-resistant ovarian cancer who have been previously treated with 1 to 3 prior systemic treatments.

Elicio Therapeutics today announced the publication of findings from a preclinical study showing enhanced anti-tumor function and eradication of solid tumors by combining its Amphiphile (AMP) platform vaccine, carrying cognate peptide and adjuvant cargos, with T cell receptor T cell therapies (TCR-Ts).

Salubris Biotherapeutics, Inc. today reported new data from Cohort 2 of the ongoing Phase 1 study evaluating JK07, the Company’s lead drug candidate, for the treatment of heart failure with reduced ejection fraction (HFrEF).

AstraZeneca advances its ambition to redefine cancer care with new data to be presented across its diverse and industry-leading portfolio of cancer medicines at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced today it would resume its existing Stock Repurchase Program.

Albany NY, United States: Advancement in scientific technology has led to development of new generation stents referred as flow diverters.

According to the business intelligence study, the global big data in healthcare market is set to grow, featuring a significant growth rate of 19.1 % over the forecast period i.e. 2018 to 2025.

Albany NY, United States: Allergy is the harmful immune reaction produced by the body to a specific substance or allergen such as dust, pollen, mite, and food.